Top Markets
#1 Derive Derive +31.84%
#2 Cross Cross +14.21%
#3 Audiera Audiera +13.22%
#4 The Bitcoin Bull The Bitcoin Bull +10.65%
#5 Geodnet Geodnet +9.21%
#6 Gama Token Gama Token +9.20%
#7 Velvet Velvet +8.25%
#8 Biconomy Biconomy +8.17%
#9 Fake World Assets Fake World Assets +8.05%
#10 Based Based +7.78%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Rank in Stocks #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Share Price
$1.84
Last synced: 2026-08-11
Market Cap
$3.51M
Change (1 day)
0.46%
Change (1 year)
-62.71%
Country
US
Trade Dogwood Therapeutics, Inc. (DWTX)

Category

Healthcare
Earnings for Dogwood Therapeutics, Inc. (DWTX)
Earnings in 2026 TTM: 0
According to Dogwood Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Dogwood Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE